Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
I'm PortAI, I can summarize articles.
Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on KalVista Pharmaceuticals with a $37.00 price target, citing positive developments in its competitive landscape and market growth potential. The RAPIDe-3 trial data alleviated concerns about IR deucrictibant's efficacy, enhancing KalVista's market position. Ekterly's efficacy is comparable to IR deucrictibant, suggesting strong market potential. Needham also maintained a Buy rating with a $28.00 target. Chatterjee is a 5-star analyst with a 30.8% average return.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments